Halozyme has completed its acquistion of Antares Pharma, creating a leading drug delivery business. View details here.
For InvestorsAntares Pharma: Making Medicines Feel Better

SEC Filings

Search By Keyword:
Filter By Year:
Filter By Type:
Showing 1 to 50 of 606
Date Title Type
2022-05-24S-8 POS - Securities to be offered to employees iS-8 POS
2022-05-24S-8 POS - Securities to be offered to employees iS-8 POS
2022-05-24S-8 POS - Securities to be offered to employees iS-8 POS
2022-05-24S-8 POS - Securities to be offered to employees iS-8 POS
2022-05-24S-8 POS - Securities to be offered to employees iS-8 POS
2022-05-24S-8 POS - Securities to be offered to employees iS-8 POS
2022-05-24S-8 POS - Securities to be offered to employees iS-8 POS
2022-05-24S-8 POS - Securities to be offered to employees iS-8 POS
2022-05-24S-8 POS - Securities to be offered to employees iS-8 POS
2022-05-24S-8 POS - Securities to be offered to employees iS-8 POS
2022-05-24S-8 POS - Securities to be offered to employees iS-8 POS
2022-05-24S-8 POS - Securities to be offered to employees iS-8 POS
2022-05-24S-8 POS - Securities to be offered to employees iS-8 POS
2022-05-24S-8 POS - Securities to be offered to employees iS-8 POS
2022-05-24POS AM - Post-Effective amendments for registratiPOS AM
2022-05-24POS AM - Post-Effective amendments for registratiPOS AM
2022-05-24POS AM - Post-Effective amendments for registratiPOS AM
2022-05-24POS AM - Post-Effective amendments for registratiPOS AM
2022-05-24POS AM - Post-Effective amendments for registratiPOS AM
2022-05-24POS AM - Post-Effective amendments for registratiPOS AM
2022-05-24POS AM - Post-Effective amendments for registratiPOS AM
2022-05-24POS AM - Post-Effective amendments for registratiPOS AM
2022-05-24POS AM - Post-Effective amendments for registratiPOS AM
2022-05-24POS AM - Post-Effective amendments for registratiPOS AM
2022-05-24POS AM - Post-Effective amendments for registratiPOS AM
2022-05-248-K - Current report8-K
2022-05-2425-NSE - Notification filed by national security 25-NSE
2022-05-24SC 14D9/A [Amend] - Solicitation, recommendation SC 14D9/A
2022-05-24SC TO-T/A [Amend] - Tender offer statement by ThiSC TO-T/A
2022-05-13SC 14D9/A [Amend] - Solicitation, recommendation SC 14D9/A
2022-05-12SC 14D9/A [Amend] - Solicitation, recommendation SC 14D9/A
2022-05-12SC TO-T/A [Amend] - Tender offer statement by ThiSC TO-T/A
2022-05-1010-Q - Quarterly report [Sections 13 or 15(d)]10-Q
2022-05-10SC 14D9/A [Amend] - Solicitation, recommendation SC 14D9/A
2022-05-06SC 13G - Statement of acquisition of beneficial oSC 13G
2022-05-05SC 14D9/A [Amend] - Solicitation, recommendation SC 14D9/A
2022-05-02SC TO-T/A [Amend] - Tender offer statement by ThiSC TO-T/A
2022-05-02SC 14D9/A [Amend] - Solicitation, recommendation SC 14D9/A
2022-04-2910-K/A [Amend] - Annual report [Section 13 and 1510-K/A
2022-04-29SC 13D - General statement of acquisition of beneSC 13D
2022-04-26SC TO-T - Tender offer statement by Third PartySC TO-T
2022-04-26SC 14D9 - Solicitation, recommendation statementsSC 14D9
2022-04-13SC14D9C - Written communication relating to thirdSC14D9C
2022-04-13SC TO-C - Written communication relating to an isSC TO-C
2022-04-13SC TO-C - Written communication relating to an isSC TO-C
2022-04-13SC TO-C - Written communication relating to an isSC TO-C
2022-04-13SC14D9C - Written communication relating to thirdSC14D9C
2022-04-138-K - Current report8-K
2022-03-078-K - Current report8-K
2022-03-038-K - Current report8-K
Showing 1 to 50 of 606